comparemela.com

Patrick Serruys News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Late-breaking Data Show Esprit BTK Drug-eluting Resorbable Scaffold Reduces Chronic Limb-threatening Ischemia Progression Compared to the Standard of Care

Abbott's landmark LIFE-BTK randomized clinical trial met its primary safety and effectiveness endpoints, demonstrating that Esprit BTK offers significant advancements in opening and keeping blocked arteries below-the-knee open compared to the standard of care, balloon angioplasty 

TCT 2023: HeartFlow Presents Clinical Data Featuring First Solution Offering Lesion-Specific Insights

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.